The weekly litigation news digest is live. Subscribe now

IP Verse

Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And An Nep Inhibitor

Patent No. EP2340828 (titled "Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And An Nep Inhibitor") was filed by Novartis on Nov 8, 2006. The application was issued on Jul 15, 2020.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (8)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ALFRED E TIEFENBACHERApr 15, 2021HAMM & WITTKOPP
BETAPHARM ARZNEIMITTELApr 15, 2021HAMM & WITTKOPP
KRKAApr 15, 2021HOFFMANN EITLE
POLPHARMAApr 15, 2021HAMM & WITTKOPP
D YOUNGApr 14, 2021D YOUNG
STADA ARZNEIMITTELApr 14, 2021KERNEBECK
SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETIApr 7, 2021SONNENHAUSER
GENERICS UKJan 19, 2021ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2340828

NOVARTIS
Application Number
EP10176094A
Filing Date
Nov 8, 2006
Status
Granted And Under Opposition
Jun 12, 2020
Publication Date
Jul 15, 2020
External Links
Slate, EP2340828B1, Google Patents